BioCentury | May 4, 2019
Product Development

Amyloid: how did we get here and what can we learn?

...long.” Merck has a tau PET imaging agent, and licensed a preclinical anti-tau antibody from Teijin Pharma Ltd....
...Inc. (NYSE:PFE), New York, N.Y. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Rodin Therapeutics Inc., Cambridge, Mass. Teijin Pharma Ltd....
BioCentury | Feb 5, 2019
Company News

Management tracks: Amazon-Berkshire Hathaway-JPM venture hires Kutan as CTO

...Mass.). Decibel also promoted Paula Cobb to COO from EVP of corporate development. Pharmaceutical company Teijin Pharma Ltd....
BioCentury | Jan 25, 2019
Clinical News

FDA panel backs Takeda's gout drug Uloric for some patient populations

...Takeda has rights to the non-purine selective inhibitor of xanthine oxidase from Teijin Pharma Ltd. (Tokyo, Japan). Teijin Pharma Ltd....
BioCentury | Dec 22, 2018
Financial News

Gossamer Bio seeks $264.5 million IPO one year after launch

...in preclinical development for oncology. Gossamer gained GB001 through the acquisition of Pulmagen Therapeutics Ltd. Teijin Pharma Ltd....
BioCentury | Aug 3, 2018
Clinical News

Amgen's Blincyto among negative CHMP opinions

...off 11%. Radius has exclusive, ex-Japanese rights to the product from Ipsen Group (Euronext:IPN; Pink:IPSEY). Teijin Pharma Ltd....
...France Portola Pharmaceuticals Inc. (NASDAQ:PTLA), South San Francisco, Calif. Radius Health Inc. (NASDAQ:RDUS), Waltham, Mass. Teijin Pharma Ltd....
BioCentury | Mar 30, 2018
Clinical News

CHMP brushes off Radius osteoporosis treatment

...2017 ). Radius has exclusive, ex-Japanese rights to the product from Ipsen Group (Euronext:IPN; Pink:IPSEY). Teijin Pharma Ltd....
...19, 2005 ). Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Radius Health Inc. (NASDAQ:RDUS), Waltham, Mass. Teijin Pharma Ltd....
...formerly BA058 Injection) Business: Musculoskeletal Allison Johnson Tymlos (BA058-SC, ITM-058, abaloparatide-sc, ba058 injection, eladynos, BIM44058) Ipsen Group Radius Health Inc. Teijin Pharma Ltd. Parathyroid...
BioCentury | Feb 16, 2018
Clinical News

Merck halts Phase III trial of AD candidate verubecestat

...early internal candidates. The product is a beta-site APP-cleaving enzyme 1 (BACE1) inhibitor. Last year, Teijin Pharma Ltd....
...CSF) total tau Status: Phase III discontinued Milestone: NA Jaime De Leon MK-8931 SCH 900931 Bionomics Ltd. Merck & Co. Inc. Teijin Pharma Ltd. Beta-site...
BioCentury | Feb 14, 2018
Clinical News

Merck halts Phase III trial of AD candidate

...early internal candidates. The product is a beta-site APP-cleaving enzyme 1 (BACE1) inhibitor. Last year, Teijin Pharma Ltd....
...an undisclosed candidate for cognitive dysfunction associated with AD. Jaime De Leon MK-8931 SCH 900931 verubecestat Bionomics Ltd. Merck & Co. Inc. Teijin Pharma Ltd. Microtubule-associated...
BioCentury | Feb 8, 2018
Company News

Management tracks: CRISPR, Arcturus

...COO. He was CEO and chief technology officer at Edinburgh Molecular Imaging Ltd. (Edinburgh, U.K.). Teijin Pharma Ltd....
BioCentury | Sep 22, 2017
Clinical News

FDA approves Ipsen's Somatuline Depot for carcinoid syndrome

...and neuroendocrine tumors in 70 countries, and is marketed outside the U.S. as Somatuline Autogel. Teijin Pharma Ltd....
...development and marketing deal for the compound in Japan. Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Teijin Pharma Ltd....
...Japan Product: Somatuline Autogel (Somatuline Depot) lanreotide acetate (ITM-014) Business: Cancer Jennie Walters ITM-014 lanreotide acetate Somatuline Autogel Somatuline Depot Ipsen Group Teijin Pharma Ltd. Somatostatin...
Items per page:
1 - 10 of 167
BioCentury | May 4, 2019
Product Development

Amyloid: how did we get here and what can we learn?

...long.” Merck has a tau PET imaging agent, and licensed a preclinical anti-tau antibody from Teijin Pharma Ltd....
...Inc. (NYSE:PFE), New York, N.Y. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Rodin Therapeutics Inc., Cambridge, Mass. Teijin Pharma Ltd....
BioCentury | Feb 5, 2019
Company News

Management tracks: Amazon-Berkshire Hathaway-JPM venture hires Kutan as CTO

...Mass.). Decibel also promoted Paula Cobb to COO from EVP of corporate development. Pharmaceutical company Teijin Pharma Ltd....
BioCentury | Jan 25, 2019
Clinical News

FDA panel backs Takeda's gout drug Uloric for some patient populations

...Takeda has rights to the non-purine selective inhibitor of xanthine oxidase from Teijin Pharma Ltd. (Tokyo, Japan). Teijin Pharma Ltd....
BioCentury | Dec 22, 2018
Financial News

Gossamer Bio seeks $264.5 million IPO one year after launch

...in preclinical development for oncology. Gossamer gained GB001 through the acquisition of Pulmagen Therapeutics Ltd. Teijin Pharma Ltd....
BioCentury | Aug 3, 2018
Clinical News

Amgen's Blincyto among negative CHMP opinions

...off 11%. Radius has exclusive, ex-Japanese rights to the product from Ipsen Group (Euronext:IPN; Pink:IPSEY). Teijin Pharma Ltd....
...France Portola Pharmaceuticals Inc. (NASDAQ:PTLA), South San Francisco, Calif. Radius Health Inc. (NASDAQ:RDUS), Waltham, Mass. Teijin Pharma Ltd....
BioCentury | Mar 30, 2018
Clinical News

CHMP brushes off Radius osteoporosis treatment

...2017 ). Radius has exclusive, ex-Japanese rights to the product from Ipsen Group (Euronext:IPN; Pink:IPSEY). Teijin Pharma Ltd....
...19, 2005 ). Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Radius Health Inc. (NASDAQ:RDUS), Waltham, Mass. Teijin Pharma Ltd....
...formerly BA058 Injection) Business: Musculoskeletal Allison Johnson Tymlos (BA058-SC, ITM-058, abaloparatide-sc, ba058 injection, eladynos, BIM44058) Ipsen Group Radius Health Inc. Teijin Pharma Ltd. Parathyroid...
BioCentury | Feb 16, 2018
Clinical News

Merck halts Phase III trial of AD candidate verubecestat

...early internal candidates. The product is a beta-site APP-cleaving enzyme 1 (BACE1) inhibitor. Last year, Teijin Pharma Ltd....
...CSF) total tau Status: Phase III discontinued Milestone: NA Jaime De Leon MK-8931 SCH 900931 Bionomics Ltd. Merck & Co. Inc. Teijin Pharma Ltd. Beta-site...
BioCentury | Feb 14, 2018
Clinical News

Merck halts Phase III trial of AD candidate

...early internal candidates. The product is a beta-site APP-cleaving enzyme 1 (BACE1) inhibitor. Last year, Teijin Pharma Ltd....
...an undisclosed candidate for cognitive dysfunction associated with AD. Jaime De Leon MK-8931 SCH 900931 verubecestat Bionomics Ltd. Merck & Co. Inc. Teijin Pharma Ltd. Microtubule-associated...
BioCentury | Feb 8, 2018
Company News

Management tracks: CRISPR, Arcturus

...COO. He was CEO and chief technology officer at Edinburgh Molecular Imaging Ltd. (Edinburgh, U.K.). Teijin Pharma Ltd....
BioCentury | Sep 22, 2017
Clinical News

FDA approves Ipsen's Somatuline Depot for carcinoid syndrome

...and neuroendocrine tumors in 70 countries, and is marketed outside the U.S. as Somatuline Autogel. Teijin Pharma Ltd....
...development and marketing deal for the compound in Japan. Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Teijin Pharma Ltd....
...Japan Product: Somatuline Autogel (Somatuline Depot) lanreotide acetate (ITM-014) Business: Cancer Jennie Walters ITM-014 lanreotide acetate Somatuline Autogel Somatuline Depot Ipsen Group Teijin Pharma Ltd. Somatostatin...
Items per page:
1 - 10 of 167